Epitomee Medical Ltd

Tel Aviv Stock Exchange EPIT.TA

Epitomee Medical Ltd Price to Sales Ratio (P/S) on January 14, 2025: 27.93

Epitomee Medical Ltd Price to Sales Ratio (P/S) is 27.93 on January 14, 2025, a 123.75% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Epitomee Medical Ltd 52-week high Price to Sales Ratio (P/S) is 122.75 on December 20, 2024, which is 339.50% above the current Price to Sales Ratio (P/S).
  • Epitomee Medical Ltd 52-week low Price to Sales Ratio (P/S) is 8.50 on August 12, 2024, which is -69.56% below the current Price to Sales Ratio (P/S).
  • Epitomee Medical Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 19.04.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Tel Aviv Stock Exchange: EPIT.TA

Epitomee Medical Ltd

CEO Dr. Radan Hashimshony Ph.D.
IPO Date Dec. 15, 2021
Location Israel
Headquarters 19 Tarshish
Employees 42
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.

StockViz Staff

January 15, 2025

Any question? Send us an email